Marriott Cambridge, MA

Progress made in last two years, we need faster advancement. Thanks to all attendees and those who came for far away.
Opening comments by Master of Ceremonies – Dr Andrew Plump, Chief Medical & Scientific Officer, Member of the Board of Directors, Takeda Pharmaceuticals

Biomedical field, important issues are covered today. Karun is a Force of Nature. Guests from India, welcome.

The most difficult field in Medicine, opportunities in Academia and in Industry — in last ten years these two groups merged in interest to solve the problem, Genetics work with Neuro to develop drugs, pathology and Neurologist discussions associations with immunology and oncology

DO belief in Beta-Amyloid hypothesis is causal hypothesis, In early patients – reduction of plaque by the drug very quickly, Early CLinical Trial, progression monitoring, TAU present and spread beyond temporal lobe, microglial cells can be protected, helpful to preserve neurons,

Need to understand Pathways,

know how to mitigate risk along the way, reduce risk of investment in a disease solution may not come by instead of investment on a drug for a disease curalble NEURO is more difficult